THE GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SIZE WAS VALUED AT USD 104.07 BILLION IN 2021 AND IS EXPECTED TO REACH USD 154.24 BILLION BY 2027, GROWING AT A CAGR OF 6.78%.

The Global Anti-Inflammatory Drugs Market Size, Share, Trends, Analysis by

  • Drug Class: Biologics & Biosimilars, NSAIDs, Steroids, and Others
  • Application: Autoimmune Diseases, Respiratory Diseases, and Others
  • Route of Administration: Parenteral, Oral, Topical, Inhalation
  • Geography: North America, Europe, APAC, Latin America, Middle East and Africa

Industry Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share, & Forecast 2022-2027

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

326 Pages

icon-table

117 Tables

icon-chart

170 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

36 Companies

icon-market

4 Market Segment

ANTI-INFLAMMATORY DRUGS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (2027) USD 154.24 Billion
Market Size (2021) USD 104.07 Billion
CAGR (2022-2027) 6.78%
Base Year 2021
Forecast Year 2022-2027
Market Segments Drug Class (Biologics & Biosimilars, NSAIDs, Steroids, and Others), Application (Autoimmune Diseases, Respiratory Diseases, and Others), Route of Administration (Parenteral, Oral, Topical, Inhalation)
Geographic Analysis North America, Europe, APAC, Latin America, Middle East And Africa

ANTI-INFLAMMATORY DRUGS MARKET SIZE ANALYSIS

Anti-inflammatory drugs (NSAIDs) are the drugs that help to treat a variety of common inflammatory conditions such as rheumatoid arthritis, IBD tendinitis, bursitis, etc. Inflammation is a defensive response of the body's immune system to diseases or infections. During many infectious and non-infectious diseases, it is the first symptom shown by the body, and if untreated, it often leads to irreversible damage and even death. Inflammation is considered one of the major causes of the development of many chronic diseases like cancer, diabetes, obesity, cardiovascular diseases, osteoporosis, rheumatoid arthritis, asthma, inflammatory bowel disease, and CNS-related diseases such as Parkinson's disease and depression. Inflammation can be acute, sub-acute, and chronic.

The global anti-inflammatory therapeutics market size was valued at USD 104.07 billion in 2021 and is expected to reach USD 154.24 billion by 2027, growing at a CAGR of 6.78%.

  • Acute Inflammation: Tissue damage due to microbial invasion, trauma, or toxic compounds can induce acute inflammation in people. It starts rapidly, becomes severe in a short time, and manifests symptoms that are likely to last for a few days. Cellulitis and acute pneumonia are typical examples of acute inflammation.
  • Sub-acute Inflammation: The period between acute and chronic inflammation usually lasts for 2 to 6 weeks.
  • Chronic Inflammation: Chronic inflammation is slow, long-term inflammation that lasts for extended periods, ranging from several months to years. The extent and effect of chronic inflammation vary based on the cause of injury and the ability of the person's body to repair and overcome the damage. Inflammation-related diseases are one of the significant causes of mortality and morbidity worldwide. Many epidemiological studies have shown that the prevalence of inflammation-associated diseases is increasing worldwide.

The growing incidence of autoimmune disorders worldwide, including rheumatoid osteoarthritis, psoriatic arthritis, multiple sclerosis, and other conditions such as gout and osteoarthritis, contributes to the global anti-inflammatory market growth. These diseases are cured by anti-inflammatory drugs, including NSAIDs, branded biologics, biosimilars, steroids, and other drug categories like disease-modifying antirheumatic drugs.

Anti-Inflammatory Drugs Market

Surge in Availability of Approved Biosimilars to Treat Inflammatory Diseases

  • Over the last two decades, a transformation has occurred in treating many chronic and highly complex inflammatory diseases like autoimmune disorders and respiratory diseases.
  • Although a broad range of anti-inflammatory drugs is prescribed to treat various inflammatory diseases, most approved small molecules are known to have many adverse effects. Due to these negative effects, there is a growing demand for safe and effective drugs, such as branded biologics and biosimilars.
  • The introduction of biosimilars a decade ago was a breakthrough and a promising approach to minimizing the costs associated with therapies for inflammatory conditions. As branded biologics are costly, the demand for biosimilars, which are similar versions of familiar biologic medications, is increasing across the globe.
  • The manufacturing cost of biosimilars is relatively lower by around 30%-40% compared to branded biologics manufacturing, and therefore, prescribing biosimilars offers an option to treat a more significant number of patients.
  • Many renowned regulatory bodies such as The European Medicines Agency (EMA), the US FDA, CFDA, and the Japanese Ministry of Health, Labour and Welfare (MHLW) are likely to approve biosimilars for the treatment of various inflammatory diseases.
  • The US FDA has approved many biosimilars to treat inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, as well as juvenile idiopathic arthritis, and other related conditions such as psoriasis and inflammatory bowel disease.

Favorable Patient Demographics

  • Chronic disabling conditions, such as immune-mediated inflammatory diseases, adversely affect people in terms of impaired function, physical suffering, pain, and the overall impact on their quality of life. In addition to the significant burden on patients and their families, inflammatory diseases represent a sizable burden on society due to high healthcare and non-healthcare healthcare-related costs.
  • The prevalence of acute and chronic inflammatory conditions among people is increasing at an alarming rate worldwide. Many epidemiological studies have shown that the prevalence of these diseases associated with inflammation is likely to increase worldwide in the coming years.
  • Almost 4% of the world's population suffers from over 80 different autoimmune disorders, the most common of which are type 1 diabetes, multiple sclerosis, rheumatoid arthritis (RA), psoriasis, Crohn's disease, and scleroderma. Autoimmune diseases are the third most common cause of chronic illness in the US.
  • Globally, the annual incidence of RA is about 3 per 10,000 people; the prevalence is about 1%, increases with age, and peaks between 35 and 50. RA affects all populations but is much more common in some groups (for example, 56% in some Native American groups) and much less frequently in others (for example, the Caribbean).
  • With advances in drug discovery and development, new classes of therapies have been developed, which have transformed the treatment of inflammatory diseases by targeting other vital proteins and signaling pathways in the body.

Prescription to OTC Drugs Switching Among Patients

  • The global pharmaceutical industry is worth more than USD 1 trillion. The industry consists of many innovative medicines prescribed by physicians in different healthcare settings and physicians, including over-the-counter (OTC) medicines, which are general-use medicines that do not require a prescription. OTC drugs are playing an increasingly important role in the global healthcare ecosystem
  • The popularity of OTC drugs is growing at a healthy rate due to the rising costs of prescription drugs and increasing concerns associated with the safety of prescription drugs. The rise in consumption of OTC drugs for specific disorders, such as those related to stressful, painful, and inflammatory conditions, is also a contributing factor to the rapid surge in the total value of OTC drugs sales worldwide.
  • The shift from Rx drugs to OTC drugs is increasing among all patient groups. In the past 30 years, the US FDA converted more than 700 prescription drugs to OTC status. The global accessibility of various drugs adds pressure and has the potential to expand OTC drugs availability.
  • In addition, the originator/developer of prescription drugs often drives the decision to switch an Rx drug to OTC. This trend is likely the result of new strategies being adopted by prescription drug manufacturers.
  • According to estimates, around 75%–85% of people in North America prefer private-label drugs due to lower prices. The market share of private label drugs is increasing in almost all therapeutic categories, including inflammatory diseases.

GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SHARE AND SEGMENTS

The global anti-inflammatory drugs market report includes market size, share, and analysis of the segments based on drug class, route of administration (ROA), application, and geography.

Biologics & biosimilars accounted for more than 60% of the market share and are anticipated to retain their dominant position during the forecast period. Biologics have better safety and efficacy than small molecule drugs available to treat inflammatory diseases. Further, the introduction of biosimilars resulted in high cost -savings in the treatment of chronic inflammatory diseases, as they are cheaper and yet as effective as biologically equivalent versions of biologics. Since the first biosimilar was approved, the regulatory authorities have approved 26 biosimilars till now, with around 11 in the US market.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the second major revenue contributor, while the steroids segment accounted for around 12%. NSAIDs act as anti-inflammatory therapeutics by inhibiting the enzyme cyclooxygenase (COX) that converts arachidonic acid into eicosanoids such as thromboxane, prostaglandins, and prostacyclin. The consumption of NSAIDs increased due to widespread use in pain management and cardiac and cerebrovascular diseases. NSAIDs are amongst the most frequently used medications worldwide, with over 70 million prescriptions.

Inflammatory diseases are also treated by steroids such as corticosteroids, which can also be used to induce remission or decrease morbidity in autoimmune disorders. Although high doses of steroids can be administered to patients given for short periods, the goal is to reach a specific goal with the minimum effective dose. Patients in need of long-term treatment should be educated about the side effects of corticosteroids, especially the risk of adrenal insufficiency, osteoporosis, and cataracts. Prednisone is a steroid with anti-inflammatory properties. It is used to treat inflammation of ulcerative colitis and Crohn's disease.

The autoimmune diseases segment accounted for more than 65%of the global anti-inflammatory drugs market share in 2021. This segment is likely to witness the highest absolute growth and incremental growth during the forecast period. The high prevalence of autoimmune diseases due to lifestyle changes and the rise in resistance against several existing therapies lead to the high demand for anti-inflammatory drugs therapy.

The treatment of autoimmune disorders focuses on controlling the autoimmune response with the help of immunosuppressive drugs. Corticosteroids can be used to suppress inflammation and suppress the immune system. Other drug options depend on the autoimmune disorder. For example, biological agents are widely used today to treat rheumatoid arthritis or other types of inflammatory arthritis. Asthma and COPD affect more than 500 million individuals worldwide, representing the most persistent inflammatory disease. Asthma impacts 10%–12% of the adult population in Europe and, along with severe bronchial allergies, accounts for high annual healthcare expenses in the region. The standard anti-inflammatory corticosteroids are the mainstay remedy for mild-moderate bronchial allergies.

In 2021, the parenteral anti-inflammatory therapeutics market accounted for the highest revenue share, followed by the oral, topical, and inhalation segments. Regulatory bodies globally have approved many new and generic anti-inflammatory drugs which can be administered through oral, parenteral, topical, and inhalation routes of administration. The biologics and biosimilar drugs are available with a parenteral route of administration. NSAIDs are commonly available as oral tablets. NSAIDs for topical use are also available (diclofenac sodium 1.5 percent topical solution, diclofenac hydroxyethyl pyrrolidine patch 1.3%, and diclofenac sodium gel 1%). Inhalation therapy is majorly used for acute or chronic respiratory diseases such as COPD, asthma, etc. Inhaled anti-inflammatory agents benefit from producing a significant local effect on airway smooth muscle with relatively lesser potential for systemic toxicity. The development of inhalation technologies has revolutionized the treatment algorithm for asthma and COPD.

In 2021, North America dominated the global anti-inflammatory drugs market and accounted for close to 40% revenue share. The US is the key revenue contributor to the North American anti-inflammatory drugs market due to the surge in awareness of the benefits of anti-inflammatory drugs against various autoimmune diseases and a subsequent rise increase in the demand for them.

Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.

The APAC anti-inflammatory drugs market is expected to witness rapid growth during the forecast period. APAC is expected to emerge as the major destination for developing and manufacturing biosimilars, generic, and OTC drugs for treating many inflammatory diseases.

Latin America, the Middle East, and Africa are expected to witness moderate growth in the coming years with the emergence of pharmaceutical & biopharmaceutical companies outsourcing their products to small and mid-sized manufacturers in these regions.

Insights by Drug Class

  • Steroids
  • NSAIDs
  • Biologics & Biosimilars
  • Other Drug Classes

Insights by Application

  • Autoimmune Diseases
  • Respiratory Diseases
  • Other Diseases

Insights by Route of Administration (ROA)

  • Parenteral
  • Oral
  • Topical
  • Inhalation

Insights by Geography

  • North America
  • Europe
  • APAC
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

How big is the Non-steroidal anti-inflammatory drugs (NSAIDs) market?

The Non-steroidal anti-inflammatory drugs (NSAIDs) market is expected to reach USD 27.65 billion by 2027.

What is the estimated value of the global anti-inflammatory drugs market in 2027?

The global anti-inflammatory drugs market was valued at USD 104.07 billion in 2021 and is expected to reach USD 154.24 billion by 2027, growing at a CAGR of 6.78%.

What are the factors driving the growth of the Non-steroidal anti-inflammatory drugs (NSAIDs) market?

The consumption of NSAIDs increased due to widespread use in pain management and in cardiac and cerebrovascular diseases. NSAIDs are amongst the most frequently used medications worldwide, with over 70 million prescriptions.

Which region will witness the fastest growth in the global anti-inflammatory drugs market?

The Asia-pacific region will witness the fastest growth during 2022-2027.

What is the market share of the North American anti-inflammatory drugs market?

In 2021, North America dominated the global anti-inflammatory drugs market and accounted for close to 40% revenue share. The US is the key revenue contributor.

Download Free Sample

The global anti-inflammatory drugs market was valued at USD 104.07 billion in 2021 and is expected to reach USD 154.24 billion by 2027, growing at a CAGR of 6.78%.

The following factors are likely to contribute to the growth of the global anti-inflammatory drugs market during the forecast period:

  • Rising OTC Buying behavior of Anti-inflammatory drugs Among Larger Patient Groups
  • Rising Prevalence of a Broad Range of Inflammatory Diseases
  • Increasing Use of Biologics for Treating Inflammatory Diseases

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Key Vendors

  • AbbVie
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Amgen
  • Biogen
  • Bristol Myers Squibb
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Actiza Pharmaceutical
    • Business Overview
    • Product Offerings
  • Allergan
  • Antibe Therapeutics
  • Aurinia Pharmaceuticals
  • AstraZeneca
  • Aurobindo Pharma
  • Bayer
  • Bio-Thera Solutions
  • Cadila Pharmaceuticals
  • Cipla
  • Celltrion
  • CENTURION REMEDIES
  • Dr. Reddy's Laboratories
  • Eisai
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Lupin
  • Medico Remedies
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries
  • Swedish Orphan Biovitrum
  • UCB
  • FUJIFILM KYOWA KIRIN BIOLOGICS
  • Teva pharmaceuticals

Segmentation by Drug Class

  • Biologics & Biosimilars
  • NSAIDs
  • Steroids
  • Others

Segmentation by Application

  • Autoimmune Diseases
  • Respiratory Diseases
  • Others

Segmentation by Route of Administration

  • Parenteral
  • Oral
  • Topical
  • Inhalation

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.4 MARKET SEGMENTATION

4.4.1 MARKET SEGMENTATION BY DRUG CLASS

4.4.2 MARKET SEGMENTATION BY APPLICATION

4.4.3 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

4.4.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

7.1.1 EPIDEMIOLOGY OF INFLAMMATORY DISEASES

7.1.2 TREATMENT OF INFLAMMATORY DISEASES

8 MARKET OPPORTUNITIES & TRENDS

8.1 PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES

8.2 SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES

8.3 RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS

9 MARKET GROWTH ENABLERS

9.1 PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS

9.2 RISING PREVALENCE OF INFLAMMATORY DISEASES

9.3 GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES

10 MARKET RESTRAINTS

10.1 PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS

10.2 SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS

10.3 PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES

11 MARKET LANDSCAPE

11.1 MARKET OVERVIEW

11.1.1 MARKET SIZE & FORECAST

11.1.2 INSIGHTS BY GEOGRAPHY

11.1.3 INSIGHTS BY DRUG CLASS

11.1.4 INSIGHTS BY APPLICATION

11.1.5 INSIGHTS BY ROUTE OF ADMINISTRATION

11.2 FIVE FORCES ANALYSIS

11.2.1 THREAT OF NEW ENTRANTS

11.2.2 BARGAINING POWER OF SUPPLIERS

11.2.3 BARGAINING POWER OF BUYERS

11.2.4 THREAT OF SUBSTITUTES

11.2.5 COMPETITIVE RIVALRY

12 DRUG CLASS

12.1 MARKET SNAPSHOT & GROWTH ENGINE

12.2 MARKET OVERVIEW

12.3 BIOLOGICS & BIOSIMILARS

12.3.1 MARKET OVERVIEW

12.3.2 MARKET SIZE & FORECAST

12.4 NSAIDS

12.4.1 MARKET OVERVIEW

12.4.2 MARKET SIZE & FORECAST

12.5 STEROIDS

12.5.1 MARKET OVERVIEW

12.5.2 MARKET SIZE & FORECAST

12.1 OTHERS

12.1.1 MARKET OVERVIEW

12.1.2 MARKET SIZE & FORECAST

13 APPLICATION

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 AUTOIMMUNE DISEASES

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.4 RESPIRATORY DISEASES

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.5 OTHERS

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

14 ROUTE OF ADMINISTRATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 PARENTERAL

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.4 ORAL

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.5 TOPICAL

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

14.6 INHALATION

14.6.1 MARKET OVERVIEW

14.6.2 MARKET SIZE & FORECAST

15 GEOGRAPHY

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 GEOGRAPHIC OVERVIEW

16 NORTH AMERICA

16.1 MARKET OVERVIEW

16.2 MARKET SIZE & FORECAST

16.2.1 NORTH AMERICA: DRUG CLASS SEGMENTATION

16.2.2 NORTH AMERICA: INDICATION SEGMENTATION

16.2.3 NORTH AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION

16.3 KEY COUNTRIES

16.3.1 US: MARKET SIZE & FORECAST

16.3.2 CANADA: MARKET SIZE & FORECAST

17 EUROPE

17.1 MARKET OVERVIEW

17.2 MARKET SIZE & FORECAST

17.2.1 EUROPE: DRUG CLASS SEGMENTATION

17.2.2 EUROPE: APPLICATION SEGMENTATION

17.2.3 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION

17.3 KEY COUNTRIES

17.3.1 GERMANY: MARKET SIZE & FORECAST

17.3.2 THE UK: MARKET SIZE & FORECAST

17.3.3 FRANCE: MARKET SIZE & FORECAST

17.3.4 ITALY: MARKET SIZE & FORECAST

17.3.5 SPAIN: MARKET SIZE & FORECAST

18 APAC

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.2.1 APAC: DRUG CLASS SEGMENTATION

18.2.2 APAC: APPLICATION SEGMENTATION

18.2.3 APAC: ROUTE OF ADMINISTERATION SEGMENTATION

18.3 KEY COUNTRIES

18.3.1 CHINA: MARKET SIZE & FORECAST

18.3.2 JAPAN: MARKET SIZE & FORECAST

18.3.3 INDIA: MARKET SIZE & FORECAST

18.3.4 AUSTRALIA: MARKET SIZE & FORECAST

18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST

19 LATIN AMERICA

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.2.1 LATIN AMERICA: DRUG CLASS SEGMENTATION

19.2.2 LATIN AMERICA: APPLICATION SEGMENTATION

19.2.3 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION

19.3 KEY COUNTRIES

19.3.1 BRAZIL: MARKET SIZE & FORECAST

19.3.2 MEXICO: MARKET SIZE & FORECAST

19.3.3 ARGENTINA: MARKET SIZE & FORECAST

20 MIDDLE EAST AND AFRICA

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.2.1 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION

20.2.2 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION

20.2.3 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTERATION SEGMENTATION

20.3 KEY COUNTRIES

20.3.1 TURKEY: MARKET SIZE & FORECAST

20.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST

20.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST

21 COMPETITIVE LANDSCAPE

21.1 COMPETITION OVERVIEW

21.2 MARKET SHARE ANALYSIS

22 KEY COMPANIES PROFILES

22.1 ABBVIE

22.1.1 BUSINESS OVERVIEW

22.1.2 PRODUCT OFFERINGS

22.1.3 KEY STRATEGIES

22.1.4 KEY STRENGTHS

22.1.5 KEY OPPORTUNITIES

22.2 AMGEN

22.2.1 BUSINESS OVERVIEW

22.2.2 PRODUCT OFFERINGS

22.2.3 KEY STRATEGIES

22.2.4 KEY STRENGTHS

22.2.5 KEY OPPORTUNITIES

22.3 BIOGEN

22.3.1 BUSINESS OVERVIEW

22.3.2 PRODUCT OFFERINGS

22.3.3 KEY STRATEGIES

22.3.4 KEY STRENGTHS

22.3.5 KEY OPPORTUNITIES

22.4 BRISTOL MYERS SQUIBB

22.4.1 BUSINESS OVERVIEW

22.4.2 PRODUCT OFFERINGS

22.4.3 KEY STRATEGIES

22.4.4 KEY STRENGTHS

22.4.5 KEY OPPORTUNITIES

22.5 ELI LILLY & COMPANY

22.5.1 BUSINESS OVERVIEW

22.5.2 PRODUCT OFFERINGS

22.5.3 KEY STRATEGIES

22.5.4 KEY STRENGTHS

22.5.5 KEY OPPORTUNITIES

22.6 F. HOFFMANN-LA ROCHE

22.6.1 BUSINESS OVERVIEW

22.6.2 PRODUCT OFFERINGS

22.6.3 KEY STRATEGIES

22.6.4 KEY STRENGTHS

22.6.5 KEY OPPORTUNITIES

22.7 GLAXOSMITHKLINE

22.7.1 BUSINESS OVERVIEW

22.7.2 PRODUCT OFFERINGS

22.7.3 KEY STRATEGIES

22.7.4 KEY STRENGTHS

22.7.5 KEY OPPORTUNITIES

22.8 JOHNSON & JOHNSON

22.8.1 BUSINESS OVERVIEW

22.8.2 PRODUCT OFFERINGS

22.8.3 KEY STRATEGIES

22.8.4 KEY STRENGTHS

22.8.5 KEY OPPORTUNITIES

22.9 MERCK & CO

22.9.1 BUSINESS OVERVIEW

22.9.2 PRODUCT OFFERINGS

22.9.3 KEY STRATEGIES

22.9.4 KEY STRENGTHS

22.9.5 KEY OPPORTUNITIES

22.10 NOVARTIS

22.10.1 BUSINESS OVERVIEW

22.10.2 PRODUCT OFFERINGS

22.10.3 KEY STRATEGIES

22.10.4 KEY STRENGTHS

22.10.5 KEY OPPORTUNITIES

22.11 PFIZER

22.11.1 BUSINESS OVERVIEW

22.11.2 PRODUCT OFFERINGS

22.11.3 KEY STRATEGIES

22.11.4 KEY STRENGTHS

22.11.5 KEY OPPORTUNITIES

23 OTHER PROMINENT VENDORS

23.1 ACTIZA PHARMACEUTICAL

23.1.1 BUSINESS OVERVIEW

23.1.2 PRODUCT OFFERINGS

23.2 ALLERGAN

23.2.1 BUSINESS OVERVIEW

23.2.2 PRODUCT OFFERINGS

23.3 ANTIBE THERAPEUTICS

23.3.1 BUSINESS OVERVIEW

23.3.2 PRODUCT OFFERINGS

23.4 AURINIA PHARMACEUTICALS

23.4.1 BUSINESS OVERVIEW

23.4.2 PRODUCT OFFERINGS

23.5 ASTRAZENECA

23.5.1 BUSINESS OVERVIEW

23.5.2 PRODUCT OFFERINGS

23.6 AUROBINDO PHARMA

23.6.1 BUSINESS OVERVIEW

23.6.2 PRODUCT OFFERINGS

23.7 BAYER

23.7.1 BUSINESS OVERVIEW

23.7.2 PRODUCT OFFERINGS

23.8 BIO-THERASOLUTIONS

23.8.1 BUSINESS OVERVIEW

23.8.2 PRODUCT OFFERINGS

23.9 CADILA PHARMACEUTICALS

23.9.1 BUSINESS OVERVIEW

23.9.2 PRODUCT OFFERINGS

23.10 CIPLA

23.10.1 BUSINESS OVERVIEW

23.10.2 PRODUCT OFFERINGS

23.11 CELLTRION

23.11.1 BUSINESS OVERVIEW

23.11.2 PRODUCT OFFERINGS

23.12 CENTURION REMEDIES

23.12.1 BUSINESS OVERVIEW

23.12.2 PRODUCT OFFERINGS

23.13 DR. REDDY’S LABORATORIES

23.13.1 BUSINESS OVERVIEW

23.13.2 PRODUCT OFFERINGS

23.14 EISAI

23.14.1 BUSINESS OVERVIEW

23.15 GILEAD SCIENCES

23.15.1 BUSINESS OVERVIEW

23.16 GLENMARK PHARMACEUTICALS

23.16.1 BUSINESS OVERVIEW

23.16.2 PRODUCT OFFERINGS

23.17 LUPIN

23.17.1 BUSINESS OVERVIEW

23.17.2 PRODUCT OFFERINGS

23.18 MEDICO REMEDIES

23.18.1 BUSINESS OVERVIEW

23.18.2 PRODUCT OFFERINGS

23.19 REGENERON PHARMACEUTICALS

23.19.1 BUSINESS OVERVIEW

23.19.2 PRODUCT OFFERINGS

23.20 SAMSUNG BIOEPIS

23.20.1 BUSINESS OVERVIEW

23.20.2 PRODUCT OFFERINGS

23.21 SANOFI

23.21.1 BUSINESS OVERVIEW

23.21.2 PRODUCT OFFERINGS

23.22 SUN PHARMACEUTICAL INDUSTRIES

23.22.1 BUSINESS OVERVIEW

23.22.2 PRODUCT OFFERINGS

23.23 SWEDISH ORPHAN BIOVITRUM

23.23.1 BUSINESS OVERVIEW

23.23.2 PRODUCT OFFERINGS

23.24 UCB

23.24.1 BUSINESS OVERVIEW

23.24.2 PRODUCT OFFERINGS

23.25 FUJIFILM KYOWA KIRIN BIOLOGICS

23.25.1 BUSINESS OVERVIEW

23.25.2 PRODUCT OFFERINGS

24 REPORT SUMMARY

24.1 KEY TAKEAWAYS

24.2 STRATEGIC RECOMMENDATIONS

25 QUANTITATIVE SUMMARY

25.1 MARKET BY DRUG CLASS

25.1.1 NORTH AMERICA: DRUG CLASS SEGMENTATION

25.1.3 EUROPE: DRUG CLASS SEGMENTATION

25.1.4 APAC: DRUG CLASS SEGMENTATION

25.1.5 LATIN AMERICA: DRUG CLASS SEGMENTATION

25.1.6 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION

25.2 MARKET BY APPLICATION

25.2.1 NORTH AMERICA: APPLICATION SEGMENTATION

25.2.2 EUROPE: APPLICATION SEGMENTATION

25.2.3 APAC: APPLICATION SEGMENTATION

25.2.4 LATIN AMERICA: APPLICATION SEGMENTATION

25.2.5 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION

25.3 MARKET BY ROUTE OF ADMINISTRATION

25.3.1 NORTH AMERICA: ROUTE OF ADMINISTRATION

25.3.2 EUROPE: ROUTE OF ADMINISTRATION

25.3.3 APAC: ROUTE OF ADMINISTRATION

25.3.4 LATIN AMERICA: ROUTE OF ADMINISTRATION

25.3.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION

25.4 MARKET BY GEOGRAPHY

25.5.1 BIOLOGICS & BIOSIMILARS: GEOGRAPHY SEGMENTATION

25.5.2 NSAIDS: GEOGRAPHY SEGMENTATION

25.5.3 STEROIDS: GEOGRAPHY SEGMENTATION

25.5.4 OTHERS: GEOGRAPHY SEGMENTATION

25.5.5 AUTOIMMUNE DISEASES: GEOGRAPHY SEGMENTATION

25.5.6 RESPIRATORY DISEASES: GEOGRAPHY SEGMENTATION

25.5.7 OTHER DISEASES: GEOGRAPHY SEGMENTATION

25.5.8 PARENTERAL: GEOGRAPHY SEGMENTATION

25.5.9 ORAL: GEOGRAPHY SEGMENTATION

25.5.10 TOPICAL: GEOGRAPHY SEGMENTATION

25.5.11 INHALATIONAL: GEOGRAPHY SEGMENTATION

26 APPENDIX

26.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF THE GLOBAL ANTI-INFLAMMATORY DRUGS MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021

EXHIBIT 3 LIST OF MAJOR INFLAMMATORY DISEASES

EXHIBIT 4 IMPACT OF PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES

EXHIBIT 5 IMPACT OF SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES

EXHIBIT 6 IMPACT OF RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS

EXHIBIT 7 IMPACT OF PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS

EXHIBIT 8 IMPACT OF RISING PREVALENCE OF INFLAMMATORY DISEASES

EXHIBIT 9 BURDEN STATISTICS FOR DIFFERENT AUTOIMMUNE DISEASES

EXHIBIT 10 COPD DISEASE BURDEN STATISTICS

EXHIBIT 11 IMPACT OF GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES

EXHIBIT 12 IMPACT OF PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS

EXHIBIT 13 IMPACT OF SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS

EXHIBIT 14 COMMON SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS

EXHIBIT 15 ADVERSE EFFECTS OF ANTI-INFLAMMATORY DRUGS

EXHIBIT 16 IMPACT OF PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES

EXHIBIT 17 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 18 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY

EXHIBIT 19 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS

EXHIBIT 20 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION

EXHIBIT 21 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION

EXHIBIT 22 FIVE FORCES ANALYSIS 2021

EXHIBIT 23 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 24 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS

EXHIBIT 25 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: INCREMENTAL GROWTH

EXHIBIT 26 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: ABSOLUTE GROWTH

EXHIBIT 27 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 28 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 ($ BILLION)

EXHIBIT 29 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 30 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 ($ BILLION)

EXHIBIT 31 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 32 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 ($ BILLION)

EXHIBIT 33 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 34 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 ($ BILLION)

EXHIBIT 35 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 36 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION

EXHIBIT 37 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION: INCREMENTAL GROWTH

EXHIBIT 38 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 39 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 ($ BILLION)

EXHIBIT 40 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 41 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 ($BILLION)

EXHIBIT 42 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 43 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 ($ BILLION)

EXHIBIT 44 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 45 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION

EXHIBIT 46 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: INCREMENTAL GROWTH

EXHIBIT 47 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: ABSOLUTE GROWTH

EXHIBIT 48 TYPES OF PARENTERAL ROUTES OF ADMINISTRATION

EXHIBIT 49 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 50 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 51 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 52 MAJOR ORAL ANTI-INFLAMMATORY DRUGS

EXHIBIT 53 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 54 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 55 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 56 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 57 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 58 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 59 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY

EXHIBIT 60 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: KEY COUNTRIES ($ BILLION)

EXHIBIT 61 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH

EXHIBIT 62 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH

EXHIBIT 63 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 64 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 65 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 66 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027

EXHIBIT 67 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 68 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 69 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027

EXHIBIT 70 US ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 71 CANADA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 72 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES

EXHIBIT 73 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 74 EUROPE ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 75 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 76 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 77 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE 2021 & 2027

EXHIBIT 79 GERMANY ANTI-INFLAMMATORY DRUGS MARKET 2020–2027 ($BILLION)

EXHIBIT 80 UK ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 81 MORTALITY PERCENTAGE ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES

EXHIBIT 82 FRANCE ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 83 ITALY ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 84 SPAIN ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 85 APAC ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES

EXHIBIT 86 APAC ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 87 APAC ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 88 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027

EXHIBIT 89 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 90 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 91 INCREMENTAL GROWTH IN APAC 2021 & 2027

EXHIBIT 92 CHINA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 93 JAPAN ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 94 INDIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 95 AUSTRALIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 96 SOUTH KOREA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 97 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES

EXHIBIT 98 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 99 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 100 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 101 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 102 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 103 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027

EXHIBIT 104 BRAZIL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 105 MEXICO ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 106 ARGENTINA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 107 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES

EXHIBIT 108 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 109 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($BILLION)

EXHIBIT 110 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 111 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027

EXHIBIT 112 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027

EXHIBIT 113 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027

EXHIBIT 114 TURKEY ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 115 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 116 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION)

EXHIBIT 117 ABBVIE: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 118 ABBVIE: R&D EXPENDITURE 2018–2020 ($ BILLION)

EXHIBIT 119 ABBVIE: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)

EXHIBIT 120 AMGEN: TOTAL REVENUE 2018–2020 ($ MILLION)

EXHIBIT 121 AMGEN: R&D EXPENDITURE 2018–2020 ($ MILLION)

EXHIBIT 122 BIOGEN: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 123 BIOGEN: REVENUE BY PRODUCT CATEGORIES 2018–2020 ($ MILLION)

EXHIBIT 124 BIOGEN: R&D EXPENDITURE 2018–2020 ($ MILLION)

EXHIBIT 125 BRISTOL MYERS SQUIBB: TOTAL REVENUE 2018–2020 ($ MILLION)

EXHIBIT 126 BRISTOL MYERS SQUIBB: R&D EXPENDITURE 2018–2020 ($ MILLION)

EXHIBIT 127 BRISTOL MYERS SQUIBB: REVENUE BY GEOGRAPHIC REGION 2020 ($ MILLION)

EXHIBIT 128 ELI LILLY & COMPANY: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 129 ELI LILLY & COMPANY: RESEARCH & DEVELOPMENT 2018–2020 ($ BILLION)

EXHIBIT 130 ELI LILLY & COMPANY: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)

EXHIBIT 131 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2019–2021 ($ BILLION)

EXHIBIT 132 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019–2021 ($ BILLION)

EXHIBIT 133 GLAXOSMITHKLINE: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 134 GLAXOSMITHKLINE: REVENUE BY BUSINESS SEGMENTS 2018–2020 ($ BILLION)

EXHIBIT 135 GLAXOSMITHKLINE: R& D EXPENDITURE 2018–2020 ($ BILLION)

EXHIBIT 136 GLAXOSMITHKLINE: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)

EXHIBIT 137 JOHNSON & JOHNSON: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 138 MERCK & CO: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 139 MERCK & CO: REVENUE BY SEGMENTS 2018–2020 ($ BILLION)

EXHIBIT 140 MERCK & CO: R&D EXPENDITURE 2018–2020 ($ BILLION)

EXHIBIT 141 NOVARTIS: TOTAL REVENUE 2018–2020 ($ MILLION)

EXHIBIT 142 NOVARTIS: R&D EXPENDITURE 2018-2020 ($ MILLION)

EXHIBIT 143 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2019–2020 ($ MILLION)

EXHIBIT 144 NOVARTIS: REVENUE BY GEOGRAPHY 2020 ($ MILLION)

EXHIBIT 145 PFIZER: REVENUE 2018–2020 ($ BILLION)

EXHIBIT 146 PFIZER: R&D EXPENDITURE 2018–2020 ($ BILLION)

EXHIBIT 147 PFIZER: REVENUE BY GEOGRAPHY 2018–2020 ($ BILLION)

EXHIBIT 148 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)

EXHIBIT 149 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 150 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 151 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 152 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 153 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 154 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 155 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 156 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 157 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 158 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 159 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 160 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 161 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 162 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 163 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 164 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 165 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 166 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 167 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 168 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)

EXHIBIT 169 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 ($ BILLION) (GEOGRAPHY)

EXHIBIT 170 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021–2027 (%) (GEOGRAPHY)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2021

TABLE 3 MAJOR PRODUCTS IN THE MANAGEMENT OF INFLAMMATORY DISEASES

TABLE 4 LIST OF MAJOR INVESTIGATIONAL THERAPIES FOR INFLAMMATORY DISEASES

TABLE 5 COST-EFFECTIVENESS OF BIOSIMILARS COMPARED WITH ORIGINATOR BIOLOGICS TO TREAT CHRONIC INFLAMMATORY CONDITIONS

TABLE 6 LIST OF POTENTIAL & APPROVED BIOSIMILARS FOR INFLAMMATORY DISEASES

TABLE 7 LIST OF RECENTLY APPROVED ANTI-INFLAMMATORY DRUGS

TABLE 8 TOP GLOBAL OTC ANTI-INFLAMMATORY DRUG BRANDS

TABLE 9 ANTI-INFLAMMATORY OFF-PATENT PRODUCTS

TABLE 10 PRODUCTS RECALLS IN THE GLOBAL ANTI-INFLAMMATORY DRUGS MARKET

TABLE 11 LIST OF MAJOR BIOLOGICS & BIOSIMILARS APPROVED FOR INFLAMMATORY DISEASES

TABLE 12 MAJOR AVAILABLE PRESCRIPTION NSAIDS

TABLE 13 COMMON EXAMPLES OF PARENTERAL ANTI-INFLAMMATORY DRUGS

TABLE 14 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 15 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 16 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021–2027 ($ BILLION)

TABLE 17 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021–2027 (%)

TABLE 18 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 19 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 20 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 21 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 22 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 23 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 24 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 25 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 26 APPROVED ANTI-INFLAMMATORY DRUGS IN GERMANY

TABLE 27 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 28 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 29 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 30 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 31 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 32 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 33 NMPA-APPROVED ANTI-INFLAMMATORY BIOSIMILARS 2019

TABLE 34 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 35 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 36 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 37 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 38 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 39 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 40 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 41 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 42 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 43 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 44 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 45 ABBVIE: MAJOR PRODUCT OFFERINGS

TABLE 46 AMGEN: MAJOR PRODUCT OFFERINGS

TABLE 47 BIOGEN: MAJOR PRODUCT OFFERINGS

TABLE 48 BRISTOL MYERS SQUIBB: MAJOR PRODUCT OFFERINGS

TABLE 49 ELI LILLY & COMPANY: MAJOR PRODUCT OFFERINGS

TABLE 50 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS

TABLE 51 GLAXOSMITHKLINE: MAJOR PRODUCT OFFERINGS

TABLE 52 JOHNSON & JOHNSON: MAJOR PRODUCT OFFERINGS

TABLE 53 MERCK & CO: MAJOR PRODUCT OFFERINGS

TABLE 54 NOVARTIS: MAJOR PRODUCT OFFERINGS

TABLE 55 PFIZER: MAJOR PRODUCT OFFERINGS

TABLE 56 ACTIZA PHARMACEUTICAL: MAJOR PRODUCT OFFERINGS

TABLE 57 ALLERGAN: MAJOR PRODUCT OFFERINGS

TABLE 58 ANTIBE THERAPEUTICS: MAJOR PRODUCT OFFERINGS

TABLE 59 AURINIA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS

TABLE 60 ASTRAZENECA: MAJOR PRODUCT OFFERINGS

TABLE 61 AUROBINDO PHARMA: MAJOR PRODUCT OFFERINGS

TABLE 62 BAYER: MAJOR PRODUCT OFFERINGS

TABLE 63 BIO-THERA SOLUTIONS: MAJOR PRODUCT OFFERINGS

TABLE 64 CADILA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS

TABLE 65 CIPLA: MAJOR PRODUCT OFFERINGS

TABLE 66 CELLTRION: MAJOR PRODUCT OFFERINGS

TABLE 67 CENTURION REMEDIES: MAJOR PRODUCT OFFERINGS

TABLE 68 DR. REDDY’S LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 69 EISAI: MAJOR PRODUCT OFFERINGS

TABLE 70 GILEAD SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 71 GLENMARK PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS

TABLE 72 LUPIN: MAJOR PRODUCT OFFERINGS

TABLE 73 MEDICO REMEDIES: MAJOR PRODUCT OFFERINGS

TABLE 74 REGENERON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS

TABLE 75 SAMSUNG BIOEPIS: MAJOR PRODUCT OFFERINGS

TABLE 76 SANOFI: MAJOR PRODUCT OFFERINGS

TABLE 77 SUN PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS

TABLE 78 SWEDISH ORPHAN BIOVITRUM: MAJOR PRODUCT OFFERINGS

TABLE 79 UCB: MAJOR PRODUCT OFFERINGS

TABLE 80 FUJIFILM KYOWA KIRIN BIOLOGICS: MAJOR PRODUCT OFFERINGS

TABLE 81 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 82 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 83 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 84 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 85 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 86 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 87 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 88 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 89 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 90 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 91 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 ($ BILLION)

TABLE 92 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021–2027 (%)

TABLE 93 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 94 GLOBAL AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 95 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 96 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 97 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 98 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 99 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 100 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 101 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 102 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 103 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 ($ BILLION)

TABLE 104 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021–2027 (%)

TABLE 105 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 106 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 107 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 108 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 109 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 110 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 111 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 112 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 113 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 114 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 115 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ BILLION)

TABLE 116 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)

TABLE 117 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021–2027 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date